PrEP

Top HIV articles of the year on Specialty Pharmacy Times.

HIV hiding in the brain can cause damage to the patient.

Syringe services programs seek to halt the spread of HIV among injection drug users.

Lack of adherence to HIV medications can create resistance since the virus mutates quickly.

Pennsylvania health department recommends that patients be screened for HIV, and hepatitis B and C viruses.

Integrase inhibitors can reduce the HIV viral load to decrease transmission of the disease.

Global HIV incidence rates drop in some African countries.

Prior research suggested that T cells become pathogenic when they encounter specific dendritic cells in the lymph nodes.

Clinicians are able to prescribe ART more liberally for HIV because of its improved adverse event profile and wider array of available drugs.

The recommended time to begin antiretroviral therapy has changed since it first arrived in the mid 90s for HIV.

Peer referrals for testing can locate people with undiagnosed HIV better than health care providers.

Portal hypertension creates problems in patients coinfected with HIV and hepatitis C virus.

Patients who have both HIV and hepatitis C, and also have portal hypertension, are a very special concern.

Cigarettes can be a bigger contributor to death in HIV patients than the virus itself.

Researchers seek to determine the best antiretroviral treatment regimen for HIV.

Finding the right combinations for antiretroviral therapy for HIV remains a challenge for researchers.

Top news of the day from across the health care landscape.

New testing procedure can quickly evaluate HIV levels in the blood.

Optimal treatment to prevent mother-to-child transmission of HIV can increase adverse events.

Link between HIV and cancer established in new report.

Newly developed technology maps HIV inserts across the human genome.

Around 14 million people have HIV worldwide – yet an estimated 40% don’t know they’re infected.

Broadly neutralizing antibodies (bNAbs) may hold the key to eliminating HIV-1.

Launch of South Africa-based clinical trial provides hope for the defeat of HIV.

Highly active antiretroviral therapy (HAART) prolongs survival for patients with HIV, but increases the risk for other chronic diseases.